2024-11-16 22:51:51
Promising Efficacy of AT101 CAR-T for Blood Cancer
Corporate/ 2023-07-24
Promising Efficacy of AT101 CAR-T for Bl...

SEOUL,South Korea,April 18,2023--AbClon,a South Korean biotech firm,presented non-clinical and phase 1 interim results of its AT101 novel CA...

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting
Corporate/ 2023-07-24
Antengene Announces Five Presentations a...

Five posters showcased progress with multiple preclinical and clinical programs,including ATG-008 (mTORC1/2 inhibitor),ATG-017 (ERK1/2 inhib...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release